Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.47 |
| ▸ | CXCR5 | P32302 | 8/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1162409 | 0.87 | GHSR (0.48) | GHSRCXCR5BACE1EPHX2PYGL | |
| SCHEMBL1162415 | 0.87 | GHSR (0.48) | GHSRCXCR5BACE1EPHX2PYGL | |
| SCHEMBL8581652 | 0.87 | GHSR (0.48) | GHSRCXCR5BACE1EPHX2PYGL | |
| SCHEMBL7916929 | 0.83 | GHSR (0.41) | GHSRBACE1MEN1NPC1HTT | |
| SCHEMBL7921532 | 0.83 | GHSR (0.41) | GHSRBACE1MEN1NPC1HTT | |
| SCHEMBL7917374 | 0.83 | GHSR (0.42) | GHSRBACE1MEN1NPC1HTT | |
| SCHEMBL2813574 | 0.83 | GHSR (0.63) | GHSRCXCR5BACE1EPHX2PYGL | |
| SCHEMBL29715495 | 0.83 | GHSR (0.63) | GHSRCXCR5BACE1EPHX2PYGL | |
| SCHEMBL18614234 | 0.83 | GHSR (0.63) | GHSRCXCR5BACE1EPHX2PYGL | |
| SCHEMBL5835834 | 0.82 | GHSR (0.54) | GHSRCXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115767-B2 | Tetraline derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | ABBVIE INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | GPR119, GHSR, GIPR | GHSR 2/4885CXCR5 1553/4885BACE1 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.